These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15546907)

  • 1. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.
    Tauchmanovà L; Ricci P; Serio B; Lombardi G; Colao A; Rotoli B; Selleri C
    J Clin Endocrinol Metab; 2005 Feb; 90(2):627-34. PubMed ID: 15546907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation.
    Tauchmanovà L; Serio B; Del Puente A; Risitano AM; Esposito A; De Rosa G; Lombardi G; Colao A; Rotoli B; Selleri C
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5058-65. PubMed ID: 12414872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation.
    Hari P; DeFor TE; Vesole DH; Bredeson CN; Burns LJ
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1361-7. PubMed ID: 23806773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Ganguly S; Divine CL; Aljitawi OS; Abhyankar S; McGuirk JP; Graves L
    Clin Transplant; 2012; 26(3):447-53. PubMed ID: 22003964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
    Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
    Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
    Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
    Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone turnover 18 months after a single intravenous dose of zoledronic acid.
    Borba VZ; Paz-Filho G; Kulak CA; Seibel MJ; Bilezikian JP
    Int J Clin Pract; 2007 Jun; 61(6):1058-62. PubMed ID: 17504370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.
    Ebeling PR; Thomas DM; Erbas B; Hopper JL; Szer J; Grigg AP
    J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
    Brufsky A; Harker WG; Beck JT; Carroll R; Tan-Chiu E; Seidler C; Hohneker J; Lacerna L; Petrone S; Perez EA
    J Clin Oncol; 2007 Mar; 25(7):829-36. PubMed ID: 17159193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.
    D'Souza AB; Grigg AP; Szer J; Ebeling PR
    Intern Med J; 2006 Sep; 36(9):600-3. PubMed ID: 16911552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.
    Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Mitterbauer C; Steininger R; Grampp S; Klaushofer K; Delling G; Oberbauer R
    Kidney Int; 2003 Mar; 63(3):1130-6. PubMed ID: 12631097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.
    Otrock ZK; Azar ST; Shamseddeen WA; Habr D; Inati A; Koussa S; Mahfouz RA; Taher AT
    Ann Hematol; 2006 Sep; 85(9):605-9. PubMed ID: 16830143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.
    Tauchmanovà L; De Simone G; Musella T; Orio F; Ricci P; Nappi C; Lombardi G; Colao A; Rotoli B; Selleri C
    Bone Marrow Transplant; 2006 Jan; 37(1):81-8. PubMed ID: 16247420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.